JAMA, Rheumatology / 04.07.2013
Early Rheumatoid Arthritis: Biological vs Conventional Treatment and Work Loss
MedicalResearch.com Interview with:
Jonas Eriksson, PhD-student
Clinical Epidemiology Unit
Karolinska Institutet, T2
171 76 STOCKHOLM
Sweden
Biological vs Conventional Combination Treatment and Work Loss in Early Rheumatoid Arthritis A Randomized Trial
MedicalResearch.com: What are the main findings of the study?
Answer: The main finding from this study is that in patients with early rheumatoid arthritis and with an insufficient response to methotrexate, addition of biologic (infliximab) or conventional combination therapy (sulfasalazine+hydroxychlorquine) resulted in significant improvements in work ability over 21 months. However, at 21 months, no significant difference could be detected in work ability change between patients randomized to addition of biologic or conventional therapy. When comparing the randomized early rheumatoid arthritis patients to matched general population comparators, the average number of days of work loss did not return to the level of the general population, underscoring the need for more effective treatment strategies and earlier diagnosis.












